Suppr
超能文献

Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis.

作者信息

Sanyal Arun J, Miller Veronica

机构信息

Department of Medicine, VCU School of Medicine, Richmond, Virginia.

University of California School of Public Health, Berkeley, California.

出版信息

Gastroenterology. 2016 Jun;150(8):1723-7. doi: 10.1053/j.gastro.2016.02.044. Epub 2016 Feb 26.

DOI:10.1053/j.gastro.2016.02.044

PMID:26924092

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6802739/

Abstract

摘要

相似文献

Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis.

Gastroenterology. 2016 Jun;150(8):1723-7. doi: 10.1053/j.gastro.2016.02.044. Epub 2016 Feb 26.

Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints.

Expert Opin Drug Discov. 2021 Feb;16(2):125-134. doi: 10.1080/17460441.2020.1811674. Epub 2020 Oct 22.

Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads.

Circ Heart Fail. 2016 Oct;9(10). doi: 10.1161/CIRCHEARTFAILURE.116.003192.

Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?

Clin Liver Dis. 2019 Feb;23(1):157-165. doi: 10.1016/j.cld.2018.09.008.

Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration.

Hepatology. 2021 May;73(5):2023-2027. doi: 10.1002/hep.31687.

End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease.

Gastroenterology. 2016 Jan;150(1):11-3. doi: 10.1053/j.gastro.2015.11.017. Epub 2015 Nov 18.

Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program.

Clin Pharmacol Ther. 2017 Apr;101(4):444-446. doi: 10.1002/cpt.560. Epub 2016 Dec 29.

Simultaneous Metabolic and Alcohol-associated Fatty Liver Disease (SMAFLD) and Simultaneous Metabolic and Alcohol-associated Steatohepatitis (SMASH).

Ann Hepatol. 2021 Sep-Oct;24:100526. doi: 10.1016/j.aohep.2021.100526.

Nonalcoholic steatohepatitis (NASH) drugs market.

Nat Rev Drug Discov. 2016 Nov 3;15(11):745-746. doi: 10.1038/nrd.2016.188.

Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway.

Drugs. 2015 Aug;75(12):1373-92. doi: 10.1007/s40265-015-0437-3.

引用本文的文献

-Allylmercaptocysteine improves alcoholic liver disease partly through a direct modulation of insulin receptor signaling.

Acta Pharm Sin B. 2021 Mar;11(3):668-679. doi: 10.1016/j.apsb.2020.11.006. Epub 2020 Nov 13.

Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis.

Sci Rep. 2019 Nov 7;9(1):16210. doi: 10.1038/s41598-019-52736-y.

Pharmacologic Management of Nonalcoholic Steatohepatitis.

Gastroenterol Hepatol (N Y). 2018 Oct;14(10):582-589.

Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials.

J Clin Transl Hepatol. 2018 Sep 28;6(3):264-275. doi: 10.14218/JCTH.2017.00056. Epub 2018 Jun 28.

Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.

Cochrane Database Syst Rev. 2017 Mar 30;3(3):CD011640. doi: 10.1002/14651858.CD011640.pub2.

Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.

Hepatology. 2017 Jun;65(6):1891-1903. doi: 10.1002/hep.29090. Epub 2017 Apr 28.

Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease.

Gastroenterology. 2016 Jun;150(8):1695-7. doi: 10.1053/j.gastro.2016.04.038. Epub 2016 May 4.

本文引用的文献

Gaps in Knowledge and Research Priorities for Alcoholic Hepatitis.

Gastroenterology. 2015 Jul;149(1):4-9. doi: 10.1053/j.gastro.2015.05.015. Epub 2015 May 23.

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Gastroenterology. 2015 Aug;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043. Epub 2015 Apr 29.

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

Hepatology. 2015 Apr;61(4):1392-405. doi: 10.1002/hep.27678. Epub 2015 Mar 19.

Alcoholic hepatitis.

Dan Med J. 2014 Oct;61(10):B4755.

Alcoholic hepatitis: Prognosis and treatment.

Gastroenterol Hepatol. 2014 Apr;37(4):262-8. doi: 10.1016/j.gastrohep.2014.02.001. Epub 2014 Mar 20.

A histologic scoring system for prognosis of patients with alcoholic hepatitis.

Gastroenterology. 2014 May;146(5):1231-9.e1-6. doi: 10.1053/j.gastro.2014.01.018. Epub 2014 Jan 15.

Alcoholic hepatitis: current challenges and future directions.

Clin Gastroenterol Hepatol. 2014 Apr;12(4):555-64; quiz e31-2. doi: 10.1016/j.cgh.2013.06.013. Epub 2013 Jun 28.

Comparison of MELD, HVPG, and their changes to predict clinically relevant endpoints in cirrhosis.

Scand J Gastroenterol. 2012 Feb;47(2):204-11. doi: 10.3109/00365521.2011.645500.

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

Gastroenterology. 2011 Oct;141(4):1249-53. doi: 10.1053/j.gastro.2011.06.061. Epub 2011 Jul 2.

Population-based risk factors and resource utilization for HCC: US perspective.

Curr Med Res Opin. 2010 Sep;26(9):2183-91. doi: 10.1185/03007995.2010.506375.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译